Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study examines patients with chronic kidney disease-related anemia and measures changes
in the metabolism of the heart using FDG/PET scanning, before and 6 months after their
health-care provider has initiated anemia management therapy with the FDA-approved drug
darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The
investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic
kidney disease but this improves after correction of this anemia with darbepoetin alfa.
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore